EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes

Cas S Dejonckheere, Julian P Layer, Motaz Hamed, Katharina Layer, Andrea Glasmacher, Lea L Friker, Anna-Laura Potthoff, Thomas Zeyen, Davide Scafa, David Koch, Stephan Garbe, Jasmin A Holz und 11 weitere

Journal of Neuro-Oncology · 2023-09 · 164 (3) · 683-691

DOI: 10.1007/s11060-023-04464-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 09.10.2023. Verfasst von Cas S Dejonckheere und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. cas.dejonckheere@ukbonn.de. Hauptthemen laut MEDLINE: Brain Neoplasms, Radiosurgery. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Bonn.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Intraoperative radiotherapy (IORT) has become a viable treatment option for resectable brain metastases (BMs). As data on local control and radiation necrosis rates are maturing, we focus on meaningful secondary endpoints such as time to next treatment (TTNT), duration of postoperative corticosteroid treatment, and in-hospital time.

Methods

Patients prospectively recruited within an IORT study registry between November 2020 and June 2023 were compared with consecutive patients receiving adjuvant stereotactic radiotherapy (SRT) of the resection cavity within the same time frame. TTNT was defined as the number of days between BM resection and start of the next extracranial oncological therapy (systemic treatment, surgery, or radiotherapy) for each of the groups.

Results

Of 95 BM patients screened, IORT was feasible in 84 cases (88%) and ultimately performed in 64 (67%). The control collective consisted of 53 SRT patients. There were no relevant differences in clinical baseline features. Mean TTNT (range) was 36 (9 − 94) days for IORT patients versus 52 (11 − 126) days for SRT patients ( p = 0.01). Mean duration of postoperative corticosteroid treatment was similar (8 days; p = 0.83), as was mean postoperative in-hospital time (11 versus 12 days; p = 0.97). Mean total in-hospital time for BM treatment (in- and out-patient days) was 11 days for IORT versus 19 days for SRT patients ( p < 0.001).

Conclusion

IORT for BMs results in faster completion of interdisciplinary treatment when compared to adjuvant SRT, without increasing corticosteroid intake or prolonging in-hospital times. A randomised phase III trial will determine the clinical effects of shorter TTNT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsRadiosurgeryHumansAdrenal Cortex HormonesRadiotherapy, AdjuvantTreatment OutcomeProspective Studies

Stichwörter der Autor:innen

Brain metastasisIntraoperative radiotherapyStereotactic radiotherapyTime to next treatment

Substanzen

Adrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Radiation Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. cas.dejonckheere@ukbonn.de.
  • Department of Radiation Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
  • Institute of Experimental Oncology, University Hospital Bonn, 53127, Bonn, Germany.
  • Department of Neurosurgery, University Hospital Bonn, 53127, Bonn, Germany.
  • Institute of Neuropathology, University Hospital Bonn, 53127, Bonn, Germany.
  • Division of Clinical Neuro-Oncology, Department of Neurology, University Hospital Bonn, 53127, Bonn, Germany.

Förderung

  • Universitätsklinikum Bonn

Zitieren

APA

Dejonckheere, C. S., Layer, J. P., Hamed, M., Layer, K., Glasmacher, A., Friker, L. L., Potthoff, A. L., Zeyen, T., Scafa, D., Koch, D., Garbe, S., Holz, J. A., Kugel, F., Grimmer, M., Schmeel, F. C., Gielen, G. H., Forstbauer, H., Vatter, H., Herrlinger, U., …, & Sarria, G. R. (2023). Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes. Journal of Neuro-Oncology, 164(3), 683-691. https://doi.org/10.1007/s11060-023-04464-7

Vancouver

Dejonckheere CS, Layer JP, Hamed M, Layer K, Glasmacher A, Friker LL, et al. Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes. Journal of Neuro-Oncology. 2023;164(3):683-691. doi:10.1007/s11060-023-04464-7

BibTeX
@article{Dejonckheere2023,
  author = {Dejonckheere, Cas S and Layer, Julian P and Hamed, Motaz and Layer, Katharina and Glasmacher, Andrea and Friker, Lea L and Potthoff, Anna-Laura and Zeyen, Thomas and Scafa, Davide and Koch, David and Garbe, Stephan and Holz, Jasmin A and Kugel, Fabian and Grimmer, Molina and Schmeel, Frederic Carsten and Gielen, Gerrit H and Forstbauer, Helmut and Vatter, Hartmut and Herrlinger, Ulrich and Giordano, Frank A and Schneider, Matthias and Schmeel, Leonard Christopher and Sarria, Gustavo R},
  title = {Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes},
  journal = {Journal of Neuro-Oncology},
  year = {2023},
  volume = {164},
  number = {3},
  pages = {683--691},
  doi = {10.1007/s11060-023-04464-7}
}
Kostenlos starten →